8-K current report · filed Sep 11, 2026

Exelixis Inc (EXEL) 8-K Current Report: September 11, 2026

Item 8.01EXEL overview

Short answer

Exelixis Inc (EXEL) filed an 8-K current report with the SEC on September 11, 2026 reporting Item 8.01 (Other Events). FDA review of zanzalintinib plus atezolizumab for metastatic colorectal cancer extended three months.

Exelixis Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • FDA review of zanzalintinib plus atezolizumab for metastatic colorectal cancer extended three months
  • Updated PDUFA action date: March 3, 2027
  • Extension follows FDA designation of submitted safety and efficacy data as a major amendment
  • Regulatory decision delayed, postponing potential U.S. approval and related commercial launch timing

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Exelixis Inc 8-K filings

Get the next EXEL 8-K as it lands

Follow EXEL for push alerts, or ask the research agent what this filing means.